ClinicalTrials.gg

Program

Carbidopa

Also written as “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, “Levodopa-carbidopa intestinal gel” and “Carbidopa/levodopa/entacapone”.

Its studies are mostly in Parkinson Disease · Dyskinesias · Attention Deficit Disorder with Hyperactivity · Fibromyalgia · Disruptive, Impulse Control, and Conduct Disorders, led by 7 companies.

Furthest: phase 4, since Jun 30, 200521 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis80 open or runningphase 4since Jun 30, 2005Dec 10, 2004none ahead
AbbVie60 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
Orion Corporation, Orion Pharma30 open or runningphase 2since Feb 14, 2011Jun 5, 2008none ahead
Amneal Pharmaceuticals10 open or runningphase 1since Nov 30, 2023Nov 30, 2023none ahead
Osmotica Pharmaceutical US10 open or runningphase 2since Nov 12, 2007Nov 12, 2007none ahead
Shanghai WD Pharmaceutical10 open or runningphase 1since Feb 12, 2026Feb 12, 2026none ahead
SynAgile10 open or runningphase 2since Feb 22, 2021Feb 22, 2021none ahead

Also a collaborator on its studies: tfs-trial-form-support and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Dec 10, 2004.

  1. Nov 12, 2007Osmotica Pharmaceutical US's first study: phase 2 study in Parkinson DiseaseNew to Osmotica Pharmaceutical USOsmotica Pharmaceutical US · NCT00558337 · 78 enrolled · Argentina
  2. Jan 11, 2008Phase 4 study in Parkinson DiseaseNovartis · NCT00601978
  3. Mar 19, 2008Phase 4 study in Parkinson DiseaseNovartis · NCT00642356 · 14 enrolled · United States
  4. Jun 5, 2008Orion Corporation, Orion Pharma's first study: phase 1 study in PharmacokineticsNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT00693862 · 19 enrolled · Finland
  5. Feb 14, 2011Phase 2 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT01296464 · 27 enrolled · Finland, Sweden
  6. Jul 28, 2011Phase 1 study in Parkinson DiseaseAbbVie · NCT01484990 · 19 enrolled
  7. Sep 7, 2012Phase 4 study in Disruptive, Impulse Control, and Conduct DisordersNovartis · NCT01683253 · 150 enrolled · Korea, Republic of
  8. Nov 27, 2012Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT01736176 · 39 enrolled
  9. Oct 9, 2013Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT01960842 · 31 enrolled
  10. Sep 11, 2015Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT02549092 · 89 enrolled · United States, Australia, Canada and more
  11. Jan 20, 2017Phase 1 study in Healthy VolunteersOrion Corporation, Orion Pharma · NCT03055936 · 56 enrolled · Germany
  12. Feb 22, 2021SynAgile's first study: phase 2 study in Parkinson DiseaseNew to SynAgileSynAgile · NCT04778176 · 17 enrolled · Italy, Luxembourg, Spain
  13. Nov 30, 2023Amneal Pharmaceuticals's first study: phase 1 study in Cardiac Repolarization in Healthy SubjectsNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT06161220 · 35 enrolled · United States
  14. Feb 12, 2026Shanghai WD Pharmaceutical's first study: phase 1 study in HealhtyNew to Shanghai WD PharmaceuticalShanghai WD Pharmaceutical · NCT07442591 · 12 enrolled · China

TargetBeta

DDC →read by rule
“DOPA decarboxylase inhibitor”ChEMBL 37, by rule

Other programs on DDC

ProgramCompanyFurthest phaseStudies
benserazide, levodopa drug combinationruleBial - Portela Cphase 13

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07442591Healhty · China1CompletedShanghai WD PharmaceuticalApr 23, 202612
NCT06161220Cardiac Repolarization in Healthy Subjects · United States1CompletedAmneal PharmaceuticalsDec 3, 202335
NCT04778176Parkinson Disease · Italy, Luxembourg, Spain2CompletedSynAgileJul 21, 202217
NCT03055936Healthy Volunteers · Germany1CompletedOrion Corporation, Orion PharmaJun 9, 201756
NCT02549092Advanced Parkinson's Disease · United States, Australia, Canada and more3CompletedAbbVieMay 14, 202089
NCT01960842Advanced Parkinson's Disease3CompletedAbbVieMar 201531
NCT01736176Advanced Parkinson's Disease3CompletedAbbVieMar 201539
NCT01683253Disruptive, Impulse Control, and Conduct Disorders · Korea, Republic of4CompletedNovartisDec 2014150
NCT01484990Parkinson Disease1CompletedAbbVieSep 201019
NCT01296464Parkinson Disease · Finland, Sweden2CompletedOrion Corporation, Orion PharmaJul 201127
NCT00693862Pharmacokinetics · Finland1CompletedOrion Corporation, Orion PharmaApr 200819
NCT00642356Parkinson Disease · United States4TerminatedNovartisMay 200914
NCT00601978Parkinson Disease4WithdrawnNovartisNov 20090
NCT00558337Parkinson Disease · Argentina2CompletedOsmotica Pharmaceutical USDec 200878
NCT00391898Parkinson Disease · Spain4CompletedNovartisJun 200895
NCT00360568Dyskinesias · United States, Germany, New Zealand3CompletedAbbVieOct 201262
NCT00335153Dyskinesias · United States, Australia, Canada and more3CompletedAbbVieJun 2012354
NCT00143026Parkinson Disease · Australia, Philippines, Taiwan and more4CompletedNovartisJun 2006184
NCT00134966Parkinson Disease · United States, Canada, Czechia and more3CompletedNovartisSep 2007493
NCT00219284Parkinson Disease · United States, Puerto Rico4CompletedNovartisJul 2008359
NCT00099268Parkinson Disease · United States, Austria, Belgium and more3CompletedNovartisNov 2008747

How it is read

Names in the registry

  • “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, 3 entries
  • “Levodopa-carbidopa intestinal gel”, 3 entries
  • “Carbidopa/levodopa/entacapone”, 3 entries
  • “Levodopa-Carbidopa Intestinal Gel”, 2 entries
  • “Carbidopa”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.